Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cytheris' interim analysis of its ECLIPSE II Phase I/IIa study showed that treatment with Interleukin-7 (CYT107), added to peginterferon and ribavirin (SOC) in genotype one and four treatment experienced patients defined as nonresponders to SOC, induces a broad immune response associated with HCV viral clearance.
Subscribe to our email newsletter
Recombinant human interleukin-7 (CYT107) is a critical immune-modulator for immune T-cell recovery and enhancement.
ECLIPSE II is an open-label, dose-escalating study, where CYT107 was administered subcutaneously, one injection per week for four weeks as an add-on therapy to 24 or 48 weeks of SOC, peginterferon and ribavirin.
In chronic HCV patients defined as non responders to SOC, CYT107 treatment was safe and expanded both CD4 and CD8 T cells, which is believed to enhance the immune response.
The study demonstrated only one serious adverse event (AE) that did not lead to study drug discontinuation.